Campus Biotech, Geneva, Thursday, October 1, 2026
Join us for an exclusive evening co?hosted by Swiss Healthcare Licensing Group (Swiss HLG) and Gyrus Capital to explore one of the most powerful value creation strategies in healthcare and life sciences: carve-outs.
By separating non-core assets or businesses into independent companies, carve-outs can unlock hidden value, sharpen strategic focus, and create platforms for sustainable growth.
Keynote Speaker:
Market and Strategic Insights:
Investor and Operational Insights:
Networking Apéro:
Continue the conversation over drinks and refreshments while connecting with peers from Switzerland's healthcare, biotech, pharmaceutical, and investment communities.
Schedule:
Bios
Etienne Jornod: Executive Chairman of OM Pharma, Former Executive Chairman Galenica and Vifor, Former Chairman NZZ and Director Alliance Boots (KKR)
Etienne Jornod has been the Executive Chairman and Co-owner of OM Pharma since October 2020. Mr Jornod founded Optimus Holding with the goal of buying OM Pharma along with other Swiss entrepreneurs and the Turkish pharmaceutical leader Abdi Ibrahim. The ambition is to further expand OM Pharma and invest in R&D to exploit the full potential of its bacterial extracts.
In order to do this, Mr Jornod stepped down as Executive Chairman of Vifor Pharma's Board of Directors early 2020, making a public offer for OM Pharma which was then a Vifor Pharma affiliate. To avoid any conflict of interest, the sales process was managed by Rothschild.
Mr Jornod spent all of his career at Galenica-Vifor Group, were he started as Junior Product Manager at the age of 22. In 1995, he became Chairman and CEO of the Galenica Group, which took the name of the Vifor Pharma Group in 2017. Under his management the Group grew from a wholesaler, solely reserved for Swiss pharmacists, to a global group focused on two main activities: Vifor Pharma (Global Speciality Pharma Company) and Galenica Santé (Pharmacy Chain with Services and Products). In 2017, the Vifor Pharma Group sold Galenica Santé on the stock market via an IPO. Both groups were valued at more than CHF14 billion on Mr Jornod’s retirement. For 10 years, until April 2023, Mr Jornod was Chairman of the Board of Directors of the NZZ-Mediengruppe. During his career, Mr Jornod has also been a member of the board of numerous private and listed companies, such as AllianceUnichem (Footsee), AllianceBoots (KKR), Bieffe Medital, Bon Appétit and Vaudoise.
Mr Jornod holds a degree in business and economics from HEC Lausanne (lic. oec.) and graduated from the Senior Executive Program at Stanford University.
Elsa Torchet: Director, Life Sciences, Strategy and Business Design, Deloitte
Elsa is a Director in Deloitte’s Life Sciences practice with 10 years of experience working in a mid-size listed company and consulting. She advises executives on a diverse array of topics, including growth strategy, transformation, risk, and business development, with a particular focus on the precision medicine ecosystem. Elsa’s clients span regional, international, global, listed organisations, as well as privately owned and family businesses. In her advisory role, Elsa collaborates with her clients to navigate complex challenges, delivering innovative and high-quality services, and driving strategic market development.
Igor Heinzer: Partner – Head of Valuation and Modelling, Deloitte
Igor is a partner in Strategy & Transactions with more than 25 years of international experience and leads the Valuation and Business Modelling practice of Deloitte Switzerland. He has advised emerging growth companies and global leaders across the pharmaceutical, biotechnology, medtech, diagnostics and broader life sciences sector. His experience spans M&A and licensing transactions, intellectual property valuation, growth and scale-up strategies, fundraising, capital allocation, financial and tax reporting, and performance tracking. Igor regularly advises corporate development teams, C-suite executives and Boards on the financial and valuation implications of strategic decisions, investments and disruptive technologies.
Anna Mattsson: Senior Partner at McKinsey
Anna leads the Strategy & Corporate Finance Practice for Switzerland and co-leads our separation and spin-off service line worldwide. She is a globally recognized merger management and carve-out adviser specializing in supporting boards and management teams in designing, planning, and executing complex, cross-border integrations, separations, and alliances.
Anna has over 20 years of M&A experience and has supported more than 150 M&A deals, ranging from $200 million to $50 billion. She works across industries with a focus on Life Sciences, Consumer and Chemicals. She regularly lectures on M&A topics at business schools across Europe and has authored numerous studies and is co-author of the Divestiture chapter of the Valuation Book.
In addition to her work in M&A, she is also passionate about diversity and has served on multiple boards, e.g. as chairwoman of Advance, to further diversity and inclusion.
Becki Morison: CEO, Essential Pharma
Becki is a seasoned global executive with more than 25 years of experience in the pharmaceutical industry, spanning commercial leadership, market access, and large-scale organisational transformation. She is currently CEO of Essential Pharma, an international specialty pharma company. Over her career, Becki has held senior leadership roles at LEO Pharma and Eli Lilly, where she led global commercial functions, major therapeutic franchises, and country and regional organisations across Europe, Asia-Pacific, and the US. She has a track record of leading businesses through periods of significant strategic change and building high-performing teams across markets.
Robert Watson: Co-founder, Gyrus Capital
Dr. Robert Watson is the co-founder of Gyrus Capital, a Geneva-based, healthcare-focused private equity firm, and has over 20 years of investment experience in the pharma and life sciences sector. Over his career, Rob has led healthcare and life sciences investments across Europe, the US, and Asia, holding senior roles at leading investment firms in New York, London, Geneva, and Paris, including as Managing Director at Altaris Capital Partners.
We look forward to welcoming you in Geneva.
Campus Biotech, Chem. des Mines 9, Chemin des Mines 9, 1202 Genève, CH
2023 © Swiss HLG | by evago.fr
Cookies settings
